相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study
V. Dieras et al.
EUROPEAN JOURNAL OF CANCER (2013)
Cabazitaxel Plus Prednisone for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel: Results from the German Compassionate-use Programme
Axel Heidenreich et al.
EUROPEAN UROLOGY (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi et al.
LANCET ONCOLOGY (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial
Orazio Caffo et al.
BJU INTERNATIONAL (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study
C. Villanueva et al.
EUROPEAN JOURNAL OF CANCER (2011)
TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer
Stephane Oudard
FUTURE ONCOLOGY (2011)
Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
Amanda J. O'Neill et al.
MOLECULAR CANCER (2011)
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Karim Fizazi et al.
LANCET (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Horwich et al.
ANNALS OF ONCOLOGY (2010)
Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
Daniel C. Danila et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
Alison H. M. Reid et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
Gerhardt Attard et al.
CANCER CELL (2009)
Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes
Ricardo M. Attar et al.
CLINICAL CANCER RESEARCH (2009)
Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
Alain C. Mita et al.
CLINICAL CANCER RESEARCH (2009)
Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
R. Bruce Montgomery et al.
CANCER RESEARCH (2008)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
Dominik R. Berthold et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline
Thomas J. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The androgen axis in recurrent prostate cancer
JL Mohler et al.
CLINICAL CANCER RESEARCH (2004)
Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program
RB Shah et al.
CANCER RESEARCH (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Osteoclast differentiation and activation
WJ Boyle et al.
NATURE (2003)
Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats
S Cisternino et al.
BRITISH JOURNAL OF PHARMACOLOGY (2003)
分享论文
